OpenHealth Technologies, a European health tech startup specializing in the harmonization, interpretation, and analysis of laboratory data, today announced the successful closure of its pre-seed funding round, raising $1.3 million. The round was led by YZR Capital and joined by Calm/Storm, Octopus Ventures, jFund, as well as several known business angels from the HealthTech space, including Simon Krüger (Doctorlib, NewZapiens), Prof. Dr. Dr. Jörg Kriegsmann (Proteopath), Dr. Samanta DallAgnese, Dr. Carlos Ballarati, and Emilio Püschmann (Amparo, Farmalisto).
OpenHealth Technologies is a lab data harmonization and medical AI platform. With a B2B approach, it enables the health industry to unlock health data to improve patient treatment and preventive health. Clients include laboratories, health insurers, HealthTech startups, and other companies in the health/pharma, well-being, and longevity sectors.
Founded in 2023 by Gerrit Glass (N26, Formel Skin, finleap), Dr. Frederic Muench (Charité, ETH Zurich), and Frank Krueger (Baze), OpenHealth is an international tech company headquartered in Amsterdam with offices in Berlin and São Paulo.
In May, OpenHealth announced the acquisition of Bludworks Ltd., a Brazilian competitor, to accelerate growth in Latin America.
About the product: OpenHealth Technologies developed an AI infrastructure platform to analyze and harmonize laboratory results from different sources, types, and regions. Based on its platform, companies in the health industry can connect via API to access the data in a structured way, receive insights, visualizations, and enriched information to embed into their solutions or offerings (as a white-label solution) directly to their clients (B2B2X).
A few months after launch, OpenHealth Technologies is already used by several laboratories, healthtech startups (in the areas of personalized nutrition, genetic tests, hospital AI, electronic health record systems), health insurers, and the public health sector in Brazil, Germany, and the USA.
